J. Scott Garland - 07 Jan 2026 Form 3 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Director
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
07 Jan 2026
Net transactions value
$0
Form type
3
Filing time
09 Jan 2026, 18:04:07 UTC
Previous filing
07 Nov 2025
Next filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Garland J. Scott Director C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 09 Jan 2026 0001533228

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ELVN Stock Option (right to buy) 07 Jan 2026 Common Stock 13,072 $24.12 Direct F1
holding ELVN Stock Option (right to buy) 07 Jan 2026 Common Stock 13,508 $22.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Remarks:

Exhibit 24.1 - Power of Attorney